NCT02214693View on ClinicalTrials.gov

PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

March 31, 2015

Conditions
Renal Impairment
Interventions
DRUG

DA-1229

Trial Locations (1)

Unknown

Clinical Trial Center, Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT02214693 - PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients | Biotech Hunter | Biotech Hunter